Skip to Content

ASH2020: Subcutaneous Daratumumab in Multiple Myeloma shows reduced the risk of progression or death by 37%

Get an overview of the results from the phase 3 study, APOLLO, presented by Dr. Dimopoulos at ASH. New treatment for patients with refractory multiple myeloma.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top